These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3290018)

  • 21. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
    Roy TM; Broadstone VL; Peterson HR; Snider HL; Cyrus J; Fell R; Rothchild AH; Samols E; Pfeifer MA
    Diabetes Res Clin Pract; 1990; 10(1):91-7. PubMed ID: 2123430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.
    Neurology; 1993 Jun; 43(6):1141-9. PubMed ID: 8170559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
    Fagius J; Jameson S
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing.
    Greene DA
    Metabolism; 1986 Apr; 35(4 Suppl 1):60-5. PubMed ID: 2421135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients.
    Green A; Jaspan J; Kavin H; Chung S; Schoenberg H
    Diabetes Res Clin Pract; 1987 Nov; 4(1):67-75. PubMed ID: 3121273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldose reductase inhibitors in clinical practice. Preliminary studies on diabetic neuropathy and retinopathy.
    Pitts NE; Gundersen K; Mehta DJ; Vreeland F; Shaw GL; Peterson MJ; Collier J
    Drugs; 1986; 32 Suppl 2():30-5. PubMed ID: 3098543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldose reductase inhibitors: the end of an era or the need for different trial designs?
    Pfeifer MA; Schumer MP; Gelber DA
    Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.
    Jespersen J; Gram J; Christensen JE
    Haemostasis; 1986; 16(6):453-7. PubMed ID: 3108105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with sorbinil--an aldose reductase inhibitor.
    Pitts NE; Vreeland F; Shaw GL; Peterson MJ; Mehta DJ; Collier J; Gundersen K
    Metabolism; 1986 Apr; 35(4 Suppl 1):96-100. PubMed ID: 3083213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sorbinil, dietary myo-inositol supplementation, and insulin on resolution of neuroaxonal dystrophy in mesenteric nerves of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Coleman BD; Williamson JR; Tilton RG
    Diabetes; 1991 May; 40(5):574-82. PubMed ID: 1902427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldose reductase inhibition for diabetic neuropathy.
    Lancet; 1983 Oct; 2(8356):969. PubMed ID: 6138528
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of myo-inositol and sorbinil studies.
    Clements RS
    Clin Physiol; 1985; 5 Suppl 5():90-3. PubMed ID: 3938689
    [No Abstract]   [Full Text] [Related]  

  • 35. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
    Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine.
    Malone JI; Lowitt S; Corsico N; Orfalian Z
    Int J Clin Pharmacol Res; 1992; 12(5-6):237-41. PubMed ID: 1301404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes.
    Lowitt S; Malone JI; Salem AF; Korthals J; Benford S
    Metabolism; 1995 May; 44(5):677-80. PubMed ID: 7752919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
    Krentz AJ; Honigsberger L; Ellis SH; Hardman M; Nattrass M
    Diabet Med; 1992 Jun; 9(5):463-8. PubMed ID: 1611835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.